This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-29 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
=== Choosing an adhesive === Adhesives are selected based on archival properties and compatibility with textiles and treatment goals. The following criteria are evaluated: age-test performance, flexibility, bond strength, heat sealing temperature, pH, solubility, color stability, volatile emissions, and glass transition temperature (Tg). Display and storage orientation and conditions are also factored in because adhesives with high glass transition temperatures can tend to creep when applied to hanging textiles. Adhesives fall into four categories:
Bradford East MP Imran Hussain resigns as Shadow Minister for the New Deal for Working People from the opposition frontbench citing Keir Starmer's response to the Gaza war. 8 November Possession of nitrous oxide, commonly known as "laughing gas" or "NOS", is categorised as a Class C drug, making its possession illegal in the UK. Sunak says he will hold the Commissioner of the Metropolitan Police "accountable" over a pro-Palestinian march planned for Armistice Day, and meets with Sir Mark Rowley to discuss the demonstration. Members of the National Union of Rail, Maritime and Transport Workers are to vote on a revised pay offer and guarantee of job security that could end the railway strikes. The Mounjaro injection for treating obesity is approved for use in the UK by the Medicines and Healthcare products Regulatory Agency. 9 November Home Secretary Suella Braverman faces questions about her future after writing an article for The Times questioning the impartiality of the police over the way they deal with demonstrations, claiming that aggressive right-wing protesters are "rightly met with a stern response", while "pro-Palestinian mobs" are "largely ignored". The article was not cleared by Downing Street, while she ignored suggested changes to the piece made by officials. Data from NHS England shows waiting lists in England reached a record high in September 2023, with 7.77 million people waiting for treatment in England, including over a million on more than one waiting list.
Campbell and Satoshi Ōmura; she received it "for her discoveries concerning a novel therapy against Malaria". 2015: American inventor and clean water advocate Deepika Kurup invented a photocatalytic composite material that removes 100% of faecal coliform bacteria from contaminated water. Deepika won the Discovery Education 3M Young Scientist Challenge award and The US Stockholm Junior Water Prize for her work. 2015: Asha de Vos became the first Sri Lankan person to receive a PhD in marine mammal research, completing her thesis on "Factors influencing blue whale aggregations off southern Sri Lanka" at the University of Western Australia. 2016: American geophysicist Marcia McNutt became the first female president of the American National Academy of Sciences. 2016: French-Algerian particle physicist Yasmine Amhis was awarded the Jacques Herbrand Prize given by the French Academy of Sciences 2018: British astrophysicists Hiranya Peiris and Joanna Dunkley and Italian cosmologist Licia Verde were among 27 scientists awarded the Breakthrough Prize in Fundamental Physics for their contributions to "detailed maps of the early universe that greatly improved our knowledge of the evolution of the cosmos and the fluctuations that seeded the formation of galaxies". 2018: British astrophysicist Jocelyn Bell Burnell received the special Breakthrough Prize in Fundamental Physics for her scientific achievements and "inspiring leadership", worth $3 million.
Sources: en.wikipedia.org
Pharmacology is a branch of medical and biological sciences which encompasses the research, discovery, and characterization of chemicals exhibiting biological effects, alongside the elucidation of cellular and organismal function in relation to these chemicals. In contrast, pharmacy, a health services profession, is concerned with the application of the principles learned from pharmacology, pharmaceutics, medicinal chemistry, pharmacognosy, clinical pharmacy and others in its clinical settings; whether it be in a dispensing or clinical care role. In either field, the primary contrast between the two is their distinction between direct-patient care, pharmacy practice, and the science-oriented research field, inspired by pharmacology.
=== Further processing === The N-terminal fMet is removed from majority of proteins, both host and recombinant, by a sequence of two enzymatic reactions. First, peptide deformylase (PDF) deformylates it, converting the residue back to a normal methionine. Then methionine aminopeptidase (MetAP) removes the residue from the chain. MetAP only acts on proteins with second-position residues that are less bulky than valine. The N-terminal fMet, if not removed by PDF, seems to act as a degron, a signal for protein degradation.
Protonitazene is a benzimidazole derivative with potent opioid effects which has been sold over the internet as a designer drug since 2019, and has been identified in various European countries, as well as Canada, the US and Australia. It has been linked to numerous cases of drug overdose, and is a Schedule I drug in the US. It was developed by a Swiss pharmaceutical company in the 1950s as an alternative to morphine, but was never adopted due to severe side effects.
Sources: en.wikipedia.org
=== Property nationalized === In 1974, the Peruvian government nationalized properties in Peru owned by the company. Harold Logan, Grace's executive vice president, stated the company would join in governmental-level talks over compensation of expropriated American concerns. The loss of Grace's properties in Peru began in 1969 when 25,000 acres of sugarcane plantations were taken over in agrarian reform. The sugar lands were at Paramonga, 110 miles north of Lima, and at Cartavio, near Trujillo, 200 miles farther up the coast. Grace retained small mining operations producing copper, tin, and silver, in southern Peru, about 100 miles north of Juliaca. Jose E. Flores, head of W. R. Grace S.A. Peru, closed the mining operations for Grace in Latin America when the government of Peru nationalized the remaining interests.
At first, some major cities or capitals formed local Juntas on the basis of laws from the Hispanic tradition. The armed conflicts started in 1809, with short-lived juntas established to govern in Chuquisaca, La Paz and Quito opposing the government of the Supreme Central Junta of Seville. Although various regions objected to many crown policies, "there was little interest in outright independence; indeed there was widespread support for the Spanish Central Junta formed to lead the resistance against the French". While some Spanish Americans believed that independence was necessary, most who initially supported the creation of the new governments saw them as a means to preserve the region's autonomy from the French. Although there had been research on the idea of a separate Spanish American ("creole") identity separate from that of Iberia, political independence was not initially the aim of most Spanish Americans, nor was it necessarily inevitable. French forces had taken over southern Spain and forced the Supreme Junta to seek refuge in the island-city of Cádiz. The escape to Cádiz and the dissolution of the Supreme Central Junta on 29 January 1810, because of the reverses suffered after the Battle of Ocaña by the Spanish forces paid with Spanish American money, set off another wave of juntas being established in the Americas. These juntas gained their own levels of independence and autonomy from Spain through declarations in 1808–1810.
A honey bee that is away from the hive foraging for nectar or pollen will rarely sting, except when stepped on or roughly handled. Honey bees will actively seek out and sting when they perceive the hive to be threatened, often being alerted to this by the release of attack pheromones (below). Although it is widely believed that a worker honey bee can sting only once, this is only partially true: although the stinger is in fact barbed so that it lodges in the victim's skin, tearing loose from the bee's abdomen and leading to its death in minutes, this only happens if the skin of the victim is sufficiently thick, such as a mammal's. Honey bees are the only hymenoptera with a strongly barbed sting, though yellow jackets and some other wasps have small barbs. The venom of the honeybee contains histamine, mast cell degranulating peptide, melittin, phospholipase A2, hyaluronidase and acid phosphatase. The three proteins in honeybee venom that are important allergens are phospholipase A2, hyaluronidase and acid phosphatase. In addition, the polypeptide melittin is also antigenic. Bumblebee venom appears to be chemically and antigenically related to honeybee venom. Bees with barbed stingers can often sting other insects without harming themselves. Queen honeybees and bees of many other species, including bumblebees and many solitary bees, have smoother stingers with smaller barbs and can sting mammals repeatedly. The sting's injection of apitoxin into the victim is accompanied by the release of alarm pheromones, a process which is accelerated if the bee is fatally injured.
H2S. Very small amounts of H2S, SF6, and probably any other sulfur containing gases, cause immediate and complete deactivation of the catalyst. It is not possible to regenerate a poisoned catalyst that has been deactivated by sulfur, by treating with either oxygen or hydrogen. If sulfur containing gases are present in the sample, a switching valve should be used either to bypass the catalyst, or to back-flush the column to vent after elution of CO2. Air or O2. Reports of oxygen poisoning seem to be rather rumors than real facts. Small amounts of air through a catalyst will not kill it but anything over about 5 cc/min will cause an immediate and continual degradation of the catalyst. Unsaturated hydrocarbons. Samples of pure ethylene cause immediate, but partial, degradation of the catalyst, evidenced by slight tailing of CO and CO2 peaks. The effect of 2 or 3 samples might be tolerable, but since it is cumulative, such gases should be backflushed or bypassed. Low concentrations do not cause any degradation. Samples of pure acetylene affect the catalyst much more severely than does ethylene. Low concentrations have no effect. Probably some carbonization with high concentrations of unsaturates occurs, resulting in the deposit of soot on the catalyst surface. It is likely that aromatics would have the same effect. Other compounds. Water has no effect on the catalyst, as well as various Freons and NH3. Here again, with NH3, there is conflicting evidence from some users, who have seen a degradation after several injections, but other researchers were not able to confirm it.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.